GSK said the mixed Phase 3 results for camlipixant mean this pill “is unlikely to transform patient care” in recurrent chronic cough. GSK is stopping work in this indication, a setback to a program once hoped to yield a new blockbuster product for the company’s respiratory drug portfolio.
The post GSK Drug From $2B Deal Sputters in Phase 3 Test in Chronic Cough appeared first on MedCity News.
